Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 2019-04-30 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 2023-06-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 2021-01-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/1/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 8/1/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 8/1/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 8.19B | |
| +2.41% | -6.33% | +43.43% | +71.02% | 63.29B | |
| -0.15% | +3.11% | +10.29% | +72.56% | 54.89B | |
| +0.57% | +4.64% | +12.82% | +89.79% | 53.28B | |
| +0.37% | +3.07% | +28.23% | +51.53% | 45.81B | |
| -1.21% | +0.95% | +20.44% | +128.58% | 43.46B | |
| -0.37% | -1.20% | +252.94% | +568.54% | 40.23B | |
| +0.05% | +6.75% | +14.48% | +56.75% | 33.45B | |
| +1.19% | -5.84% | +27.86% | -0.65% | 23.7B | |
| -0.38% | +4.55% | +37.71% | +28.10% | 23.76B | |
| Average | +0.32% | +0.33% | +49.80% | +118.47% | 42.43B | |
| Weighted average by Cap. | +0.39% | +0.55% | +48.17% | +122.11% |
Employees
355
